VYVural Taner Yilmaz

Vural Taner Yilmaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vural Taner Yilmaz has a total of 261 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-Term Outcomes of Renal Transplantation in Patients with Cystinosis

    by Fatih Ergül, Mustafa Yıluzar, Mert Ünal, Abdullah Kısaoğlu, İsmail Demiryılmaz, Vural Taner Yılmaz, Hüseyin Koçak

  • Efficacy and Safety of Induction Therapy in Kidney Transplant Recipients: A Propensity Score Matching Analysis in a Multicenter Retrospective Observational Study

    by Vural Taner Yılmaz, Erol Demir, Hüseyin Koçak, Ayşe Sinangil, Rahmi Yılmaz, Şebnem Karakan, Rezzan Eren Sadioğlu, Berna Yelken, Ebru Ok, Murathan Uyar, et al.


  • Open Access

    Determination of HLA Tissue Type According to the Etiology of Patients with Chronic Renal Failure

    by Burcu Karakus Turan, Fahri Ucar, Vural Taner Yilmaz, Yahya Kilinc, Sule Darbaş Aras, Huseyin Kocak, Nurten Sayin Ekinci, Bulent Aydinli, Habibe Sema Arslan

    Chronic kidney disease (CKD) is a prominent public health concern, is defined as functional and structural damage to the kidneys. This study aims to investigate the association between human leukocyte antigen (HLA) alleles individuals with CKD and the different etiological subgroups of diesease. Genomic DNA was obtained from peripheral blood samples of 1,079 patients with retrospective CKD and 1,111 healthy control individuals. HLA genotyping was conducted using the Luminex based low-resolution method. Allele frequency distributions were calculated with the help of Arlequin v3.11 population genetics statistics program and SPSS v23.0 program, and p<0.05 values were accepted as significant by chi-square tests. HLA A*02 (21.83%), B*35 (18.30%), DRB1*11 (21.41%) alleles were observed most frequently in individuals with CKD, respectively. In our study, B*08, B*49, B*50 alleles in the HLA B locus (p=0.002, p=0.012 p=0.009) and DRB1*03, *04 alleles in the HLA DRB1 locus (p<0.001, p<0.001) were found positively associated with CKD. A*02, A*11, A*74 alleles at the HLA A locus (p=0.003, p<0.001, p=0.009) and B*27, B*39, B* alleles at the HLA B locus 40, B*59 (p<0.001, p<0.001, p<0.001, p=0.009), DRB1*07, *08, *09, *13, *16 (p<0.001, p=0.012, p=0.007, p<0.001, p<0.001) alleles were determined as negatively associated with the disease. Among the etiological groups of CKD, cystic kidney disease (36.8%), hypertension (16.8%) and urological anomalies (16.6%) were negatively associated with the HLA-DR*13 allele. Since CKD shows serious morbidity and mortality, this comprehensive study of HLA subgroups gave an explanatory idea about which alleles associated with the disease in terms of susceptibility and protection.

  • Predictive Factors of BK Virus Development in Kidney Transplant Recipients and the Effect of Low-Dose Tacrolimus Plus Everolimus on Clinical Outcomes

    by Vural Taner Yilmaz, Abdullah Kisaoglu, Ali Avanaz, Ozgur Dandin, Deniz Ozel, Ismail Demiryilmaz, Derya Mutlu, Bahar Akkaya, Bulent Aydinli, Huseyin Kocak

    Objectives: This study aimed to determine the predictive factors of BK virus viremia/nephropathy in kidney transplant recipients and to evaluate the effects of low-dose tacrolimus plus everolimus.Materials and Methods: This study included 3654 kidney transplant recipients. The patients were divided into 2 groups: group 1 were BK virus negative (n = 3525, 96.5%) and group 2 were BK virus positive (n = 129, viremia 3.5%, nephropathy 1%). Predictive factors were determined by receiver operating characteristic curve analysis and logistic regression models. We also divided and analyzed patients with BK virus viremia/nephropathy into 2 groups according to immunosuppressive changes. Group 2a had been switched to low-dose tacrolimus plus everolimus (n = 54, 41.9%), and group 2b had been switched to other immunosuppressive protocols (n = 75, 58.1%).Results: We found that use of anti-T-cell lymphocyte globulin and tacrolimus, deceased donor transplant, and rejection were predictive factors for BK virus viremia/nephropathy. In addition, patients who had low-dose calcineurin inhibitor plus mammalian target of rapamycin inhibitor regimens showed a low rate of BK virus development (only 6.2% of all cases). In Group 2a, both the BK polyomavirus-associated nephropathy rate (n = 23 [42.6%] vs n = 12 [16%] in group 2b; P = .001) and viral load (DNA > 10(4) copies/mL) (n = 49 [90.7%] vs n = 27 [36%] in group 2b; P = .001) were increased versus group 2b. Graft function, graft survival, viral clearance, and rejection rate were similar between the groups after protocol change.Conclusions: BK virus viremia/nephropathy rate was lower in patients who received low-dose calcineurin inhibitor plus mammalian target of rapamycin inhibitor protocols; the low-dose tacrolimus plus everolimus switch protocol after BK virus was more effective and safe than other protocols.


  • Evaluation of the relationship between de‐novo DSA development and CXCR5+PD‐1+CD8+ T cells and PD‐1/PD‐L1 mRNA expression in kidney transplant recipients

    by Nurten Sayin Ekinci, Vural Taner Yilmaz, Yahya Kilinc, Huseyin Kocak, Sule Darbas, Abdullah Kisaoglu, Bulent Aydinli, Sezin Yakut Uzuner, Fahri Ucar

    Background and aims: The relationship between the Follicular Cytotoxic T cell subgroup and expression levels of PD1/PD‐L1 genes and the development of donor specific antibody (DSA) is unknown. In this study, we aimed to examine CD8+CXCR5+PD‐1+ follicular cytotoxic T cell levels and expression levels of PD1/PD‐L1 genes in peripheral blood lymphocytes in de‐novo DSA positive and negative kidney transplant recipients (KTR).Methods: In our study, expression of PD‐1/ PD‐L1 genes by Real‐Time Quantitative PCR method and CD8+CXCR5+PD‐1+ T cell expression levels by flow cytometric method were obtained from peripheral blood samples. 63 participants were included in the study (de‐novo DSA positive recipients (n = 22, group 1), de‐novo DSA negative recipients (n = 20, group 2) and healthy control (n = 21, group 3). All patients had negative PRA before kidney transplantation. Expression (%) levels of target cells were evaluated by flow cytometry method. IBM SPSS Statistics for Windows Version 22 and R.3.3.2 software were used to evaluate the data.Results: The demographic data of the groups were similar. PD‐1 mRNA expression was higher in de‐novo DSA positive KTR than negative (respectively, 1.03 ± .29/.82 ± .15, p: .001). CD8+CXCR5+PD‐1+ T cell expression levels were found to be higher in the de‐novo DSA positive group than in the negative group and similar to the healthy group (respectively, 3.06 ± 1.98/.52 ± .40, p:.001, 3.06 ± 1.98/2.78 ± .59, p:.62). The percentage of CD8+CXCR5+PD‐1+ expressing T cells was significantly lower in the HLA‐Class II+ group than other groups (HLA CI/II/ I+II, respectively, 3.63 ± 2.72/1.65 ± .50/3.68 ± 1.67, p: .04).Conclusions: In our study, a significant relationship was found between DSA formation and PD‐1 mRNA level and CD8+CXCR5+PD‐1+ follicular cytotoxic T cell in KTR.


  • Regulatory B Cells Profile in Kidney Transplant Recipients With Chronic-Active Antibody-Mediated Rejection

    by Halil Goksel Guzel, Vural Taner Yilmaz, Sadi Koksoy, Huseyin Kocak, Abdullah Kisaoglu, Mehmet Soylu, Bahar Akkaya, Ismail Demiryilmaz, Bülent Aydinli, Gultekin Suleymanlar


  • Evaluation of the effect and predictive role of vitamin D and vitamin D receptor expression in CD4 + , CD8 + , CD14 + , CD56 + cells on the development of chronic rejection and graft functions in kidney transplant patients

    by Tuba Vural, Vural Taner Yilmaz, Sadi Koksoy, Abdullah Kisaoglu, Deniz Ozel, Ismail Demiryilmaz, Bulent Aydinli, Huseyin Kocak, Gultekin Suleymanlar

    Purpose It is known that vitamin D has positive effects on graft functions (reduce fibrosis, suppress excessive inflammatory response, improve graft functions). In our study, it was aimed to evaluate the effects and predictive roles of vitamin D, the expression of vitamin D receptor (VDR) in lymphocytes, monocytes, natural killer cells on chronic rejection and graft functions in kidney transplant patients. Methods Seventy one people were included in the study and analyses were made by dividing them into 3 groups. Group 1: Healthy control (n = 29), Group 2: Kidney transplant patients with stable kidney function (n = 17), and Group 3: Kidney transplant patients with chronic rejection diagnosis (n = 25). Serum 25-hydroxycholecalciferol, 1.25 dihydroxycholecalciferol levels and VDR percentages in CD4 + , CD8 + , CD14 + , CD56 + cells were measured in 3 groups. ROC analyses and logistic regression models were performed to predict rejection and long-term graft functions. Results The percentage of VDR expression in CD4 + lymphocytes (p < 0.001) and CD14( +) monocytes (p < 0.001), 25-hydroxycholecalciferol and 1.25 dihydroxycholecalciferol levels were lower in group 3 was detected. In ROC analyses and logistic regression models, VDR expression in CD4( +)T lymphocytes was shown to have a statistically significant value in the development of chronic rejection (Odds ratio 0.86: 0.76–0.92; p = 0.001/AUC = 0.941, p < 0.001) and prediction of 5th-year graft functions (Odds ratio 0.93: 0.88–0.98; p = 0.017/AUC = 0.745, p = 0.007). Conclusion In our study, it was shown that low vitamin D and VDR expression is associated with poor outcome and VDR expression in CD4( +)T lymphocytes is predictive in terms of graft function and rejection.

  • Open Access

    Evaluation of Overall Survival and Disease-Free Survival in Patients Receiving Liver Transplantation for Hepatocellular Carcinoma and Comparison of Living Versus Deceased Donor Liver Transplants: Results of 15 Years of Experience

    by Ali Avanaz, Haydar Adanir, Abdullah Kisaoglu, Vural Taner Yilmaz, Ezgi Avanaz, Bora Dinc, Ismail Demiryilmaz, Gülsüm Özlem Elpek, Huseyin Kocak, Bulent Aydinli

    Objective: Research comparing patients who received liver transplantation (LT) for hepatocellular carcinoma (HCC) has produced varying outcomes regarding survival and disease-free survival. The objective of this study is to determine the factors that influence the disease-free and overall survivals of those who have undergone LT for HCC and to compare the outcomes of living versus deceased donor liver transplants. Materials and Methods: We retrospectively analyzed data on patients aged 18 and above who received LT for HCC from 2006 to 2022. Patients with a follow-up period of less than 6 months and who did not meet the University of California San Francisco criteria were excluded. The data from 58 patients were analyzed. We split the patients into living donor liver transplantation (LDLT) (group 1) and deceased donor liver transplantation (DDLT) (group 2). Results: The mean age was 56 ± 8.1 years. There were 49 males and 9 females. The median of the alphafetoprotein (AFP) level and model for end-stage liver disease score was 10.1 ng/mL and 11, respectively. The 1-, 3-, 5-, and 10-year disease-free survival rates were 86%, 76.5%, 76.5%, and 76.5%, respectively. The survival rates for the same periods were 94.8%, 74.9%, 70.6%, and 67.4%. The receiver operating characteristic analysis revealed that AFP > 31.8 ng/mL and a total tumor size >3.85 cm raise the likelihood of HCC recurrence post-LT. Conclusion: Based on the current literature, the overall survival and disease-free survival rates are influenced by factors such as AFP value, total tumor number, and total tumor diameter. In our study, the AFP value and total tumor size had an impact on the recurrence of HCC, and the survival rates were comparable on LDLT and DDLT. Cite this article as: Avanaz A, Adanir H, Kisaoglu A, et al. Evaluation of overall survival and disease-free survival in patients receiving liver transplantation for hepatocellular carcinoma and comparison of living versus deceased donor liver transplants: results of 15 years of experience. Eurasian J Med. 2023;55(3):254-258.

  • Tacrolimus-Associated Pure Red Cell Aplasia in a Patient With Renal Transplant

    by Orhan Kemal Yucel, Mustafa Serkan Alemdar, Bahar Akkaya, Huseyin Kocak, Gultekin Suleymanlar, Vural Taner Yilmaz

    Pure red cell aplasia is a relatively rare disease characterized by suppression or absence of erythroid precursors while other cell lineages are normal in the bone marrow. The disease could be secondary to other diseases or an adverse side effect of certain drugs. Tacrolimus is widely used as an immunosuppressive agent in solid-organ transplant without significant myelosuppressive effects. However, several tacrolimus-related pure red cell aplasia cases have been reported to date. Here, we report a case of a renal transplant recipient who developed tacrolimus-associated pure red cell aplasia in the posttransplant period and recovered dramatically after switching from tacrolimus to cyclosporine. Early diagnosis of pure red cell aplasia, which generally requires multiple blood transfusions, is very important because an increased number of blood transfusions can cause immunogenic effects and increased risk for allograft survival. Tacrolimus is a prominent drug for immunosuppression and is suspected to cause pure red cell aplasia during the posttransplant period; therefore, clinicians should consider a switch from tacrolimus to another immunosuppressive agent.


  • Prognosis and Treatment for Active and Chronic Antibody-Mediated Rejection in Renal Transplant Recipients; Single Center Experience

    by Vural Taner Yilmaz, Ozgur Dandin, Abdullah Kisaoglu, Ali Avanaz, Davut Kamaci, Havva Serap Toru, Ismail Demiryilmaz, Sadi Koksoy, Bulent Aydinli, Huseyin Kocak